Abstract
There is a cellular crosstalk between Wnt/β-catenin and Hippo/Yes-related protein 1 signaling paths in colon cancer (CC) which promotes EMT processes that mediate the metastatic progression of CC. We aimed to evaluate follistatin-like 3 (FSTL3), ADAM12, and FAT4 expressions in CC. A statistical analysis was done to establish how disease-free survival, overall survival (OS), and relapse all performed a prognostic role. High FSTL3 was detected in 68% of CC and significantly related to left-sided tumors (P = 0.002) and the advanced tumor features, such as metastasis (P = 0.010), pT (P = 0.006), high grade (P = 0.005), lymph node contribution (P = 0.013), and advanced stage (P = 0.003). Positive ADAM12 expression was observed in 60% and significantly related to left-sided tumors (P = 0.001) and significantly common in high grade (P = 0.028), lymph node involvement (P < 0.001), and advanced stage (P = 0.004). Low FAT4 expression was recognized in 76% and linked with the right-sided tumors (P = 0.036). FAT4 expression was contrariwise linked with CC grade (P < 0.001). Furthermore, FAT4 expression was inversely correlated with lymph node involvement (P = 0.002), metastasis (P = 0.046), and advanced stage (P = 0.002). During the follow-up, 14 cases were relapsed and positively associated with high FSTL3 expression (P = 0.001) and ADAM12 expression (P < 0.001), but negatively linked with FAT4 expression (P = 0.003). Shorter disease-free survival was substantially correlated with positive ADAM12, extreme FSTL3, and low FAT4 expression (P < 0.001, P = 0.002, P = 0.003, consecutively). Moreover, Kaplan-Meier curves demonstrated a significant correlation between shorter OS with extreme FSTL3, positive ADAM12, and low FAT4 (P = 0.004, <0.001, 0.019, consecutively). High FSTL3, positive ADAM12, and low FAT4 expression are unfavorable prognostic influences in CC that may be accountable for relapse and therapeutic resistance in CC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Applied immunohistochemistry & molecular morphology : AIMM
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
